{"title":"WEIGHT","description":"\u003cp\u003eEngineered for those who approach body transformation as a science. Focusing on metabolic efficiency, appetite regulation, and adipose tissue modulation through next-generation compounds. Formulated to support energy expenditure, glycemic control, and sustainable fat oxidation, these products work in synergy with the body's natural hormonal and metabolic pathways.\u003c\/p\u003e","products":[{"product_id":"retlira-30-30mg-3ml-pen","title":"RETLIRA 30 — 30mg \/ 3ml Research Pen","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eRetlira 30 — Retatrutide 30 mg Pre-Filled Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTriple-Receptor Research | Metabolic Health | Weight-Management Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eRetlira 30 is a pre-filled pen-format research product listed as containing 30 mg of retatrutide in a 3 ml presentation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRetatrutide, also known as LY3437943, is an investigational peptide being studied for its activity across three metabolic hormone receptors: GLP-1, GIP and glucagon. These pathways are involved in appetite signalling, glucose regulation and energy metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIts triple-receptor mechanism has attracted significant scientific interest because researchers are investigating whether coordinated activity across these pathways can influence body-weight regulation and other metabolic outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Clinical Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003e1. Significant Body-Weight Reduction\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eA Phase 2 clinical trial published in \u003c\/span\u003e\u003cem\u003e\u003cspan\u003eThe New England Journal of Medicine\u003c\/span\u003e\u003c\/em\u003e\u003cspan\u003e in 2023 evaluated retatrutide in 338 adults with obesity or overweight and a weight-related complication, excluding diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAfter 48 weeks, average body-weight reductions were:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e1 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 8.7%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e4 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 17.1%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e8 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 22.8%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e12 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 24.2%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThe placebo group experienced an average reduction of 2.1%.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese results demonstrated substantial weight reduction in the studied population. They reflect a specific clinical trial and do not predict results from Retlira 30.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e2. Triple-Receptor Activity\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eRetatrutide's defining research feature is its activity across GLP-1, GIP and glucagon receptors. Researchers are investigating how these pathways interact in the regulation of appetite, energy intake and energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis mechanism distinguishes retatrutide from compounds that target only GLP-1 or both GLP-1 and GIP receptors.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e3. Waist Circumference and Body-Composition Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eIn the Phase 2 trial, average waist-circumference reductions ranged from approximately 6.5 cm to 19.6 cm across the retatrutide groups, compared with 2.6 cm in the placebo group.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings provide additional evidence of changes in body measurements during the study. They should not be interpreted as guaranteed outcomes or as proof of specific changes in muscle mass or body composition.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e4. Metabolic Health Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eResearchers are investigating retatrutide's potential effects on glucose regulation and other cardiometabolic markers. Its multi-receptor activity makes it an important subject of ongoing metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, the evidence remains under development, and further clinical trials are needed to establish its safety, long-term effects and potential clinical applications.\u003c\/span\u003e\u003c\/p\u003e","brand":"Health-Tech","offers":[{"title":"Default Title","offer_id":48258932998369,"sku":"RETLIRA30","price":1990.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Retlira.png?v=1783589534"},{"product_id":"dex-pharma-tirz-max-pen-60mg-3ml","title":"Dex Pharma Tirz Max Pen - 60mg\/3mL","description":"\u003cp\u003eDex Pharma Tirz Max Pen 60mg\/3mL — Research-Grade Tirzepatide Pen\u003c\/p\u003e\n\u003cp\u003eDex Pharma Tirz Max Pen 60mg\/3mL is a high-strength tirzepatide research product supplied in a 3mL pen format for controlled laboratory and scientific research applications.\u003c\/p\u003e\n\u003cp\u003eThe presentation contains a defined 60mg total quantity of tirzepatide research material in a convenient pen format. The product is positioned within metabolic and peptide research, with tirzepatide studied for its activity across GIP and GLP-1 receptor pathways.\u003c\/p\u003e\n\u003cp\u003eThis product is supplied strictly for research purposes and is not intended for human consumption, self-administration, diagnosis, treatment, prevention or veterinary use.\u003c\/p\u003e\n\u003cp\u003eResearch Overview\u003c\/p\u003e\n\u003cp\u003eTirzepatide is a synthetic peptide investigated for its interaction with both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor pathways.\u003c\/p\u003e\n\u003cp\u003eLaboratory and scientific research into tirzepatide includes investigation of receptor signalling, metabolic pathways, peptide-receptor interactions and related biochemical mechanisms.\u003c\/p\u003e\n\u003cp\u003eProduct Information\u003c\/p\u003e\n\u003cp\u003e• Product: Dex Pharma Tirz Max Pen\u003cbr\u003e• Active compound: Tirzepatide\u003cbr\u003e• Total quantity: 60mg\u003cbr\u003e• Volume: 3mL\u003cbr\u003e• Format: Research pen\u003cbr\u003e• Supplier\/Brand: Dex Pharma\u003cbr\u003e• Product vendor: Xander\u003cbr\u003e• Research category: Metabolic Research\u003cbr\u003e• Intended use: Laboratory research only\u003c\/p\u003e\n\u003cp\u003eResearch Areas\u003c\/p\u003e\n\u003cp\u003eTirzepatide may be of interest to researchers investigating:\u003c\/p\u003e\n\u003cp\u003e• GIP receptor signalling\u003cbr\u003e• GLP-1 receptor signalling\u003cbr\u003e• Metabolic research\u003cbr\u003e• Peptide-receptor interactions\u003cbr\u003e• Cellular signalling\u003cbr\u003e• Biochemical research\u003cbr\u003e• Metabolic pathway research\u003c\/p\u003e\n\u003cp\u003eResearch Context\u003c\/p\u003e\n\u003cp\u003eTirzepatide is widely studied as a dual GIP and GLP-1 receptor agonist. Research findings should be interpreted within the context of the relevant scientific literature and should not be treated as evidence of clinical efficacy for this research product.\u003c\/p\u003e\n\u003cp\u003eResearch-Use Notice\u003c\/p\u003e\n\u003cp\u003eThis product is supplied strictly for laboratory and scientific research purposes. It is not intended for human consumption, self-administration, diagnosis, treatment, prevention or veterinary use.\u003c\/p\u003e","brand":"Dex Pharma","offers":[{"title":"Default Title","offer_id":48259054469345,"sku":"DEXTIRZMAX60","price":2690.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/ChatGPTImageApr29_2026_09_52_25AM.png?v=1777450804"},{"product_id":"dex-pharma-reta-max-50mg-3ml-pen","title":"Dex Pharma R3ta Max 50mg\/3mL Pen","description":"\u003cp\u003e\u003cspan\u003eThe 50mg\/3ml R3t@trutide (GLP-3RT) pen is a next-generation metabolic optimizer that targets three different receptors: GLP-1, GIP, and Glucagon. This \"triple agonist\" approach makes it exceptionally powerful for weight management and metabolic health.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eR3t@trutide is often called a \"3-Way Agonist\" because it targets three metabolic pathways simultaneously, making it more potent than Semaglutide or Tirzepatide. By activating GLP-1, GIP, and Glucagon receptors, it addresses weight loss through appetite suppression and increased energy expenditure.\u003c\/p\u003e\n\u003cp data-end=\"1886\" data-start=\"1862\"\u003e✓ 50mg total R3t@trutide\u003c\/p\u003e\n\u003cp data-end=\"1916\" data-start=\"1888\"\u003e✓ Up to 25 weeks at 2mg\/week\u003c\/p\u003e\n\u003cp data-end=\"1987\" data-start=\"1918\"\u003e✓ Equivalent cost from approximately R118\/week at introductory dosing\u003c\/p\u003e\n\u003cp data-end=\"2041\" data-start=\"1989\"\u003e✓ Triple-agonist technology (GLP-1 + GIP + Glucagon)\u003c\/p\u003e\n\u003cp data-end=\"2105\" data-start=\"2043\"\u003e✓ Better mg-per-rand value than many competing pre-filled pens\u003c\/p\u003e\n\u003ch3\u003e\u003cstrong\u003eDetailed Mechanism\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGLP-1 \u0026amp; GIP:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThese work together to slow digestion, suppress appetite, and improve how your body handles insulin.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlucagon Power:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eThis third receptor is the \"secret sauce\"—it increases your resting metabolic rate and targets fat burning in the liver.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTriple Synergy:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eCombining these three allows for significant weight loss with potentially better metabolic protection than single or dual-agonist peptides.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48268204376289,"sku":null,"price":2700.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/DexReta1.png?v=1777805164"},{"product_id":"mots-c-2ml-multi-dose-pen-200-clicks","title":"Noventra MOTS-c – 2ml\/10mg Multi Dose Pen (200 Clicks)","description":"\u003cp\u003eNoventra MOTS-c is a mitochondrial-derived peptide formulated to support cellular energy production, metabolism, fat utilization, and overall metabolic performance. This advanced peptide is commonly explored for its potential role in improving endurance, insulin sensitivity, and energy efficiency at the cellular level.\u003c\/p\u003e\n\u003cp\u003eDesigned for individuals seeking enhanced fat metabolism and performance support,MOTS-c may assist with stubborn fat reduction while helping preserve lean muscle mass. The formulation is also associated with improved recovery,increased vitality,and enhanced focus through optimized mitochondrial activity.\u003c\/p\u003e\n\u003cp\u003eDelivered in a convenient \u003cstrong data-start=\"791\" data-end=\"829\"\u003e2ml Multi Dose Pen with 200 clicks\u003c\/strong\u003e, MOTS-c offers precise dosing and easy subcutaneous administration. The peptide is designed for consistent peptide delivery and is commonly used in metabolic optimization, recovery enhancement, and performance-focused protocols.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48375621681377,"sku":null,"price":790.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra_Pharma_MOTS-c_multi-dose_pen.png?v=1778962943"},{"product_id":"semaglutide-2ml-multi-dose-pen-200-clicks","title":"Noventra Semaglutide – 2ml\/6mg Multi Dose Pen (200 Clicks)","description":"\u003cp\u003eNoventra Semaglutide is a GLP-1 receptor agonist peptide formulated to support effective weight management, appetite control, and metabolic health. This advanced peptide is widely researched for its ability to help regulate hunger signals, improve satiety, and support sustainable body composition goals.\u003c\/p\u003e\n\u003cp\u003eThe formulation is designed to assist with reducing calorie intake by promoting feelings of fullness while supporting blood sugar regulation and metabolic efficiency. Semaglutide is commonly used in structured weight management protocols alongside nutrition and lifestyle modifications.\u003c\/p\u003e\n\u003cp\u003eDelivered in a convenient \u003cstrong data-start=\"758\" data-end=\"796\"\u003e2ml Multi Dose Pen with 200 clicks\u003c\/strong\u003e, the product allows for precise and consistent weekly dosing through subcutaneous administration. The easy-to-use pen system supports gradual dosage escalation protocols for optimized tolerance and long-term consistency.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48376685396193,"sku":null,"price":1360.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/semaglutide_peptide_pen.png?v=1779005539"},{"product_id":"retrexa-hybrid-44mg-2-4ml-multi-dose-pen-240-clicks","title":"Noventra Retrexa Hybrid R3t@trutide \u0026 Naltrexone Pen 44mg","description":"\u003cp\u003eRetrexa Hybrid is an advanced metabolic peptide blend combining R3t@trutide 32mg and Naltrexone 12mg in a single multi-dose pen for weight management support. This formulation is designed to activate GLP-1, GIP, and glucagon receptors to help support appetite regulation, reduced cravings, improved insulin sensitivity, and sustained energy levels. Delivered in a convenient 2.4ml multi-dose pen with 240 clicks, it allows for precise weekly dosing for individuals seeking enhanced metabolic efficiency and body composition support.\u003c\/p\u003e\",Health Tech,Health \u0026amp; Beauty \u0026gt; Health Care,\",\",true,Title,Default Title,,,,,,,,,0.0,shopify,0,continue,manual,2750.00,,true,false,,,,,,https:\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Retrexa_Hybrid_multi-dose_peptide_pen.png?v=1779006495,1,Retrexa Hybrid multi-dose pen and packaging on a reflective surface with a starry night sky background,false,,,,adults,,,,,,,,,,,,,,,,,,,,,kg,,1850.00,active\nretrexa-hybrid-44mg-2-4ml-multi-dose-pen-240-clicks,Noventra Retrexa Hybrid R3t@trutide \u0026amp; Naltrexone Pen 44mg,\"\u003cp\u003eRetrexa Hybrid is an advanced metabolic peptide blend combining R3t@trutide 32mg and Naltrexone 12mg in a single multi-dose pen for weight management support. This formulation is designed to activate GLP-1, GIP, and glucagon receptors to help support appetite regulation, reduced cravings, improved insulin sensitivity, and sustained energy levels. Delivered in a convenient 2.4ml multi-dose pen with 240 clicks, it allows for precise weekly dosing for individuals seeking enhanced metabolic efficiency and body composition support.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48376691556577,"sku":null,"price":2220.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Retrexa_Hybrid_multi-dose_peptide_pen.png?v=1779006495"},{"product_id":"tirreta-2-4ml-multi-dose-pen-240-clicks","title":"Noventra TirReta – 2.4ml\/60mg Multi Dose Pen (240 Clicks)","description":"\u003cp\u003eNoventra TirReta is an advanced dual-pathway metabolic peptide blend combining \u003cstrong data-start=\"179\" data-end=\"220\"\u003eTirzepatide 30mg and R3t@trutide 30mg\u003c\/strong\u003e in a single formulation. Designed to support aggressive weight management protocols, this hybrid peptide system targets \u003cstrong data-start=\"341\" data-end=\"379\"\u003eGLP-1, GIP, and glucagon receptors\u003c\/strong\u003e to enhance appetite control, metabolic efficiency, and fat utilization.\u003c\/p\u003e\n\u003cp\u003eThe formulation is commonly used to support extreme appetite suppression, improved blood glucose control, enhanced fat oxidation, and preservation of lean muscle during calorie restriction phases. TirReta is designed for individuals seeking advanced body recomposition and high-level metabolic support.\u003c\/p\u003e\n\u003cp\u003eDelivered through a convenient \u003cstrong data-start=\"824\" data-end=\"864\"\u003e2.4ml Multi Dose Pen with 240 clicks\u003c\/strong\u003e, TirReta allows for structured weekly dosing with precise click-based administration. The peptide blend is formulated to provide consistent appetite regulation, metabolic support, and sustained fat-loss assistance throughout progressive protocols.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48376705876193,"sku":null,"price":2290.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra_Pharma_Tirreta_multi-dose_peptide_pen.png?v=1779007186"},{"product_id":"upret-30mg","title":"UPA Upret 30MG Self-mix Vial + bact water","description":"\u003ch2 data-section-id=\"ae261s\" data-start=\"863\" data-end=\"935\"\u003eUPA Upret 30 MG (R3t@trutide) –Self-Mix - Advanced Triple-Agonist Metabolic Support\u003c\/h2\u003e\n\u003cp data-start=\"937\" data-end=\"1258\"\u003eUpret 30 MG is an advanced R3t@trutide formulation designed to support comprehensive metabolic optimization through its unique triple-receptor mechanism. By targeting GLP-1, GIP, and glucagon pathways simultaneously, R3t@trutide has emerged as one of the most exciting investigational peptides in modern obesity research.\u003c\/p\u003e\n\u003cp data-start=\"1260\" data-end=\"1423\"\u003eR3t@trutide is being studied for its ability to influence appetite regulation, improve satiety, enhance energy expenditure, and support healthy metabolic function.\u003c\/p\u003e\n\u003cp data-start=\"1425\" data-end=\"1585\"\u003eIts multi-pathway approach distinguishes it from first-generation GLP-1 therapies by addressing several mechanisms involved in weight regulation simultaneously.\u003c\/p\u003e","brand":"UPA","offers":[{"title":"Default Title","offer_id":48473879838945,"sku":null,"price":1850.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/2b3ff92e-583e-49a6-bb7f-5350555a7e0a.png?v=1781252257"},{"product_id":"dex-pharma-tesamorelin-pro-30mg-3ml","title":"Dex Pharma Tesamorelin Pro 30mg\/3mL | Research Peptide","description":"\u003cp\u003e\u0026lt;h2\u0026gt;Dex Pharma Tesamorelin Pro 30mg\/3mL\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;\u0026lt;strong\u0026gt;Dex Pharma Tesamorelin Pro 30mg\/3mL\u0026lt;\/strong\u0026gt; is a research peptide formulation containing tesamorelin, a synthetic analogue of growth hormone-releasing hormone (GHRH). Tesamorelin is studied for its interaction with the growth hormone (GH) axis and has been investigated in research involving body composition, visceral adipose tissue, growth hormone signalling and metabolic physiology.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;This product is presented by Health-Tech for \u0026lt;strong\u0026gt;research and educational purposes only\u0026lt;\/strong\u0026gt;. It is not presented as a treatment, therapy or recommendation for human use.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;What Is Tesamorelin?\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;\u0026lt;strong\u0026gt;Tesamorelin\u0026lt;\/strong\u0026gt; is a synthetic peptide analogue of GHRH. Research into tesamorelin focuses primarily on its ability to stimulate the body's growth hormone-releasing pathway and the downstream signalling associated with growth hormone and insulin-like growth factor 1 (IGF-1).\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Because of its relationship with the GH\/IGF-1 axis, tesamorelin has become an important subject in research examining \u0026lt;strong\u0026gt;body composition, visceral adipose tissue, metabolic physiology and endocrine signalling\u0026lt;\/strong\u0026gt;.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Tesamorelin Research Overview\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Research involving tesamorelin has explored how GHRH pathway stimulation may influence growth hormone secretion and downstream physiological processes.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Studies have investigated tesamorelin in areas including:\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;ul\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;Growth hormone and GHRH signalling\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;IGF-1-related endocrine pathways\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;Visceral adipose tissue research\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;Body composition research\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;Metabolic physiology\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;Endocrine and peptide research\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;Long-term investigation of the GH\/IGF-1 axis\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;\/ul\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;The research surrounding tesamorelin provides a useful model for examining how targeted peptide signalling can interact with the body's endocrine system.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;How Does Tesamorelin Work?\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Tesamorelin is designed to act as an analogue of \u0026lt;strong\u0026gt;growth hormone-releasing hormone (GHRH)\u0026lt;\/strong\u0026gt;. Research indicates that GHRH signalling can stimulate the pituitary gland to release growth hormone, which can subsequently influence downstream pathways including IGF-1.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;This makes tesamorelin particularly relevant to researchers investigating the relationship between:\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;\u0026lt;strong\u0026gt;GHRH → Growth Hormone → IGF-1 → Downstream Metabolic \u0026amp;amp; Physiological Signalling\u0026lt;\/strong\u0026gt;\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;The exact biological response can vary according to research model, experimental conditions and individual biological factors.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Key Tesamorelin Research Areas\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Visceral Adipose Tissue Research\u0026lt;\/h3\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Tesamorelin has been extensively investigated in relation to \u0026lt;strong\u0026gt;visceral adipose tissue\u0026lt;\/strong\u0026gt;, making it a notable compound within body-composition research.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Growth Hormone Research\u0026lt;\/h3\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Because of its relationship with the GH\/IGF-1 axis, tesamorelin has become an important subject in research examining body composition, visceral adipose tissue, metabolic physiology and endocrine signalling. For a deeper scientific overview, explore our \u0026lt;a href=\"https:\/\/health-tech.co.za\/blogs\/news\/tesamorelin-exploring-the-science-behind-growth-hormone-releasing-peptide-research\"\u0026gt;Tesamorelin research guide\u0026lt;\/a\u0026gt;.\u0026lt;\/p\u0026gt;\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Metabolic Research\u0026lt;\/h3\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Tesamorelin is also relevant to research examining metabolic physiology and the relationship between endocrine signalling and body composition.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Endocrine Signalling\u0026lt;\/h3\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;The compound provides researchers with a model for investigating GHRH-mediated signalling and downstream endocrine responses.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Why Is Tesamorelin Studied?\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Tesamorelin is of research interest because it provides a way to investigate the \u0026lt;strong\u0026gt;GHRH–growth hormone–IGF-1 pathway\u0026lt;\/strong\u0026gt; without directly administering growth hormone itself.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;This distinction makes tesamorelin particularly relevant to research examining the regulation of endogenous growth hormone secretion and its relationship with body composition and metabolic physiology.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Research Reference \u0026amp;amp; Study Protocol Notes\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Research protocols involving tesamorelin vary substantially according to the study design, research model, formulation and experimental objective. Researchers should consult the relevant peer-reviewed literature and institutional protocols when designing or interpreting research involving tesamorelin.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;Health-Tech does not provide human-use dosing instructions, treatment recommendations or personalised protocols for this research product.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Dex Pharma Tesamorelin Pro Specifications\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;ul\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Product:\u0026lt;\/strong\u0026gt; Tesamorelin Pro\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Brand:\u0026lt;\/strong\u0026gt; Dex Pharma\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Research compound:\u0026lt;\/strong\u0026gt; Tesamorelin\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Quantity:\u0026lt;\/strong\u0026gt; 30mg\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Format:\u0026lt;\/strong\u0026gt; 3mL research formulation\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Research category:\u0026lt;\/strong\u0026gt; Peptide Research\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;li\u0026gt;\u0026lt;strong\u0026gt;Research areas:\u0026lt;\/strong\u0026gt; GHRH signalling, growth hormone research, IGF-1 research, body composition and metabolic research\u0026lt;\/li\u0026gt;\u003cbr\u003e\u0026lt;\/ul\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Frequently Researched Questions About Tesamorelin\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;What is tesamorelin?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been studied for its effects on growth hormone signalling and related physiological pathways.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;What is tesamorelin research focused on?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Research has examined tesamorelin in areas including the GH\/IGF-1 axis, visceral adipose tissue, body composition, endocrine signalling and metabolic physiology.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;What is GHRH?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Growth hormone-releasing hormone (GHRH) is a naturally occurring hypothalamic hormone involved in regulating growth hormone secretion from the pituitary gland.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;How does tesamorelin relate to growth hormone?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Tesamorelin is a GHRH analogue and is therefore studied for its ability to interact with pathways involved in endogenous growth hormone secretion.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;What is the GH\/IGF-1 axis?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;The GH\/IGF-1 axis describes a connected endocrine signalling pathway involving growth hormone and insulin-like growth factor 1, among other regulatory components.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Why is tesamorelin studied in body composition research?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Tesamorelin has been investigated in relation to visceral adipose tissue and body composition, making it relevant to researchers studying endocrine and metabolic pathways.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Is tesamorelin a peptide?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Yes. Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;What makes tesamorelin different from growth hormone?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Tesamorelin is a GHRH analogue that acts on the pathway involved in endogenous growth hormone secretion, whereas growth hormone itself is a downstream hormone in that pathway.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;What research areas are associated with tesamorelin?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Research areas include growth hormone signalling, IGF-1, GHRH, visceral adipose tissue, body composition, endocrine physiology and metabolic research.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h3\u0026gt;Where can I learn more about tesamorelin?\u0026lt;\/h3\u0026gt;\u003cbr\u003e\u0026lt;p\u0026gt;Researchers should consult peer-reviewed scientific literature, clinical-trial records and authoritative scientific resources when evaluating tesamorelin research.\u0026lt;\/p\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;h2\u0026gt;Research Use Disclaimer\u0026lt;\/h2\u0026gt;\u003c\/p\u003e\n\u003cp\u003e\u0026lt;p\u0026gt;\u0026lt;strong\u0026gt;For research and educational purposes only.\u0026lt;\/strong\u0026gt; This product is supplied for laboratory and scientific research purposes and is not presented as a medicine, treatment or therapeutic product. Health-Tech does not provide medical advice, diagnosis, treatment recommendations or human-use protocols for research compounds. Researchers are responsible for ensuring that their work complies with all applicable laws, regulations, institutional requirements and safety procedures.\u0026lt;\/p\u0026gt;\u003cbr\u003e\u003c\/p\u003e","brand":"Dex Pharma","offers":[{"title":"Default Title","offer_id":48609015496929,"sku":null,"price":2500.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/dex-pharma-tesamorelin-pro-30mg-3ml.png?v=1787302308"},{"product_id":"maglira-5-5mg","title":"UPA Maglira 5 - 5mg pen","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eMaglira 5 — Semaglutide Pre-Filled Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Health | Appetite Regulation | Weight-Management Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eMaglira 5 is a pre-filled pen labelled as containing semaglutide, a GLP-1 receptor agonist studied extensively for its role in appetite regulation, blood-glucose control and body-weight management.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSemaglutide mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose regulation and appetite signaling. Its effects on these pathways have made it an important focus of clinical research into obesity, type 2 diabetes and associated metabolic health outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Clinical Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003e1. Significant Body-Weight Reduction\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe landmark STEP 1 clinical trial, published in \u003c\/span\u003e\u003cem\u003e\u003cspan\u003eThe New England Journal of Medicine\u003c\/span\u003e\u003c\/em\u003e\u003cspan\u003e, evaluated once-weekly semaglutide 2.4 mg in adults with overweight or obesity without diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAfter 68 weeks, participants receiving semaglutide alongside lifestyle intervention experienced an average body-weight reduction of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e14.9%\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, compared with 2.4% in the placebo group.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAdditionally, 50.5% of participants receiving semaglutide achieved at least 15% weight reduction, compared with 4.9% of participants receiving placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings demonstrate the potential of semaglutide in the studied population. They are not a prediction of results from Maglira 5.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e2. Appetite Regulation and Energy Intake\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSemaglutide acts on GLP-1 receptors involved in appetite signalling and food intake. Clinical research has demonstrated that treatment with studied semaglutide formulations can reduce energy intake and support sustained body-weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndividual outcomes vary, and these findings should not be interpreted as a guarantee of appetite suppression or weight loss with this specific product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e3. Blood-Glucose Regulation\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSemaglutide has demonstrated improvements in glycaemic control in clinical trials involving people with type 2 diabetes. It supports glucose regulation through glucose-dependent effects on insulin secretion and other GLP-1-related mechanisms.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe extent of these effects depends on the formulation, clinical indication and individual circumstances.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e4. Cardiometabolic Health Markers\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eIn STEP 1, semaglutide treatment was associated with improvements in several measured cardiometabolic risk factors, including waist circumference, blood pressure, glycated haemoglobin and lipid measurements.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings support continued research into semaglutide's role in metabolic health. Improvements in individual markers do not necessarily translate into identical clinical outcomes for every person or product.\u003c\/span\u003e\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48661161771233,"sku":null,"price":1250.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Maglira_5_-_5mg_pen_1.png?v=1785036477"},{"product_id":"bodypharm-semaglutide-6mg-multi-dose-injection-pen","title":"BodyPharm Semaglutide 6mg Multi-Dose Injection Pen","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eBodyPharm's Semaglutide 6mg pen is a pre-filled, multi-dose subcutaneous delivery device formulated for laboratory and clinical research applications involving GLP-1 receptor agonism. Each pen contains 6mg of semaglutide, a compound extensively studied for its role in appetite regulation, glucose metabolism, and cardiometabolic health.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eThe pen is formulated with disodium phosphate dihydrate, propylene glycol, phenol, and sterile water as excipients to support compound stability throughout the research handling process. Its multi-dose design (with marked 0.25mg, 0.5mg, 0.75mg, and 1mg dial increments) allows research teams to standardize dosing across study protocols without needing to reconstitute or measure from a vial.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eEach unit is single-patient\/single-subject use only, and ships in tamper-evident packaging for traceability — supporting institutions that need to maintain chain-of-custody documentation for research compounds.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eSemaglutide's GLP-1 receptor agonist mechanism has been documented across one of the largest clinical trial programs in metabolic research (the STEP trial program), with published data covering effects on body weight, glycemic control, and cardiovascular outcomes. BodyPharm's research-grade formulation is intended to support continued investigation into these mechanisms by qualified laboratories, academic institutions, and licensed investigators.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eThis product is manufactured and sold strictly for laboratory and in-vitro research purposes. It is not approved for human consumption, diagnostic use, or therapeutic administration in any jurisdiction, and is not intended for use as a food, drug, or cosmetic.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48818583142625,"sku":null,"price":3100.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Semag6.png?v=1785322744"},{"product_id":"bodypharm-semaglutide-3mg-multi-dose-injection-pen","title":"BodyPharm Semaglutide 3mg Multi-Dose Injection Pen","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eBodyPharm's Semaglutide 3mg pen is a pre-filled, multi-dose subcutaneous delivery device formulated for laboratory and clinical research applications involving GLP-1 receptor agonism. Each pen contains 3mg of semaglutide, a compound extensively studied for its role in appetite regulation, glucose metabolism, and cardiometabolic health.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eThe pen is formulated with disodium phosphate dihydrate, propylene glycol, phenol, and sterile water as excipients to support compound stability throughout the research handling process. As a lower-concentration option alongside the 6mg pen, it suits research protocols requiring smaller total volumes, finer dose titration, or shorter-duration studies. The pen ships with disposable needles for single-use administration within a research setting.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eEach unit is single-patient\/single-subject use only, and ships in tamper-evident packaging for traceability — supporting institutions that need to maintain chain-of-custody documentation for research compounds.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eSemaglutide's GLP-1 receptor agonist mechanism has been documented across one of the largest clinical trial programs in metabolic research (the STEP trial program), with published data covering effects on body weight, glycemic control, and cardiovascular outcomes. BodyPharm's research-grade formulation is intended to support continued investigation into these mechanisms by qualified laboratories, academic institutions, and licensed investigators.\u003c\/p\u003e","brand":"Body Pharma","offers":[{"title":"Default Title","offer_id":48818588287201,"sku":null,"price":2850.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/67126b31-2037-43c7-a8d1-2c26bcd56b77.png?v=1789122239"},{"product_id":"tirsema-44-tirzepatide-40mg-semaglutide-4mg-combination-pen","title":"HD Lab Tirsema 44 | Tirzepatide 40mg + Semaglutide 4mg Combination Pen","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eTirsema 44 is a pre-filled, multi-dose subcutaneous injection pen combining two GLP-1 receptor-active compounds — tirzepatide (40mg) and semaglutide (4mg) — in a single solution. Manufactured by HD Labs, the pen is intended for laboratory research applications by qualified institutions studying incretin receptor pathways.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e this is a co-formulated blend of two distinct compounds. There is currently no published clinical research evaluating tirzepatide and semaglutide combined in a single formulation — existing research on each compound has studied them individually or compared them head-to-head, not combined. This listing describes the product's composition only; it does not imply any established safety, efficacy, or research basis for the combination itself.\u003c\/p\u003e\"","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48818649104609,"sku":null,"price":2680.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/c51dc227-acc4-4ac5-9efb-b7af524de284.png?v=1785242060"},{"product_id":"ipharama-tirz-30mg-pen","title":"ipharma tirzepatide pre filled pen","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eTIRZEPATIDE 30mg — Pre-Filled Research Pen\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eProduct Overview\u003c\/strong\u003e\u003cbr\u003eTirzepatide Pre-Filled Pen is a single-compound peptide formulation supplied for laboratory and research use only. Each multi-dose pen contains 30mg of Tirzepatide, a dual GIP\/GLP-1 receptor agonist, supplied with 10 disposable injection needles. Single patient\/research-subject use only.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eComposition\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul dir=\"ltr\" class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;\" list-disc flex flex-col gap-1 pl-8 mb-3 :not=\"\" print:block=\"\" print:space-y-1=\"\"\u003e\"\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eActive peptide: Tirzepatide (GIP\/GLP-1 receptor agonist), 30mg\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eExcipients: Disodium phosphate dihydrate, Niacinamide, Phenol, Propylene glycol\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eFormat: Multi-dose pre-filled pen\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eNeedles: 10 x disposable, 31G, 8mm\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eResearch Overview\u003c\/strong\u003e\u003cbr\u003eTirzepatide is a dual GIP\/GLP-1 receptor agonist that has been extensively studied in published research for its effects on glucose metabolism, insulin sensitivity, and appetite\/energy regulation pathways. It is one of the more well-characterized incretin-mimetic compounds in current peptide research literature, with a substantial body of independent data on its receptor activity and metabolic effects.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48821141536993,"sku":null,"price":2100.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/CodexImageAug5_2026_12_05_35PM.png?v=1785924366"},{"product_id":"ipharama-tirzpsema-34mg-pen","title":"ipharma Tirzpsema 34mg\/pen","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eiPharma Tirzepsema 34 mg — Pre-Filled Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research | GLP-1 \u0026amp; GIP Signaling | Appetite Regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eiPharma Tirzepsema 34 mg is a pre-filled pen-format product marketed as a combination of tirzepatide and semaglutide, with a labelled total strength of 34 mg.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts on two metabolic hormone receptors, GIP and GLP-1, while semaglutide acts on the GLP-1 receptor. These pathways are involved in appetite signaling, blood-glucose regulation and energy balance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBoth compounds have been studied extensively in clinical research, particularly in relation to type 2 diabetes and weight management.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e1. Body-Weight Reduction\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the 72-week SURMOUNT-1 clinical trial, participants receiving tirzepatide experienced average body-weight reductions of 15.0%, 19.5% and 20.9% across the three studied dose groups.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese results were obtained using specified tirzepatide treatment regimens in adults with obesity or overweight and weight-related complications, excluding diabetes. They cannot be used to predict results from this combination product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e2. Appetite Regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eSemaglutide and tirzepatide influence incretin-related signaling pathways involved in appetite and food intake. Clinical studies of their authorized formulations have demonstrated effects on body weight, but outcomes vary by treatment, population and individual factors.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e3. Blood-Glucose Regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBoth compounds have demonstrated improvements in blood-glucose control in clinical trials involving people with type 2 diabetes. These findings apply to the specific medicinal formulations and treatment protocols studied, not automatically to an unverified combination pen.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e4. Metabolic Health Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials of tirzepatide and semaglutide have examined body weight and several cardiometabolic markers. However, evidence from separate trials does not establish that combining both compounds improves outcomes or produces a favorable overall benefit-risk profile.\u003c\/span\u003e\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48821144027361,"sku":null,"price":2550.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/5d18f37b-5961-4324-a94d-d0b81993bf5b.png?v=1785410255"},{"product_id":"ipharma-reatrutide","title":"ipharma R3t@trutide","description":"\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eR3t@trutide is a novel triple agonist peptide currently under investigation for its effects on GLP-1, GIP, and glucagon receptor pathways. This pre-filled pen format is manufactured for laboratory and research applications only, offering researchers a convenient, precision-dosed delivery device for \u003cem\u003ein vitro\u003c\/em\u003e and \u003cem\u003ein vivo\u003c\/em\u003e study protocols.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eThis product is strictly for research purposes. It is not intended for human or veterinary use, consumption, or therapeutic application.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eKey Features\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul dir=\"ltr\" class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;\" list-disc flex flex-col gap-1 pl-8 mb-3 :not=\"\" print:block=\"\" print:space-y-1=\"\"\u003e\"\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003ePre-filled, calibrated delivery pen for accurate research dosing\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eTriple receptor agonist profile (GLP-1 \/ GIP \/ Glucagon)\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eManufactured under controlled laboratory conditions\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eThird-party purity testing available (COA on request)\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003eStable formulation designed for research storage protocols\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48821177614561,"sku":null,"price":2200.0,"currency_code":"ZAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/9fba8b72-facd-4a07-a8a1-4eeb6c7ee36e_7ef6a28c-ced6-4cec-af71-4459c86084ca.png?v=1785326177"},{"product_id":"tirzepatide-30mg-vial","title":"HD Labs Tirzepatide 30mg\/vial","description":"\u003ch4 dir=\"ltr\" class=\"mt-2 -mb-1 text-base font-bold\"\u003eProduct Overview\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eTirzepatide 30 by HD Labs is a high-purity synthetic peptide formulated for laboratory and in-vitro research applications. As a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, this compound is widely studied for its role in metabolic and endocrine research. Each vial contains 30mg of lyophilized peptide, manufactured under HD Labs' quality-controlled processes and supplied with an authenticity verification system for research integrity.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eThis product is intended strictly for laboratory research purposes. It is not for human or animal consumption, diagnostic use, or therapeutic application.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch4 dir=\"ltr\" class=\"mt-2 -mb-1 text-base font-bold\"\u003eComposition\u003c\/h4\u003e\n\u003cul dir=\"ltr\" class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;\" list-disc flex flex-col gap-1 pl-8 mb-3 :not=\"\" print:block=\"\" print:space-y-1=\"\"\u003e\"\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eActive Compound:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eTirzepatide (GIP\/GLP-1 receptor agonist)\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eConcentration:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e30mg per vial\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eLyophilized powder\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eManufactured to research-grade standards\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003ePackaging:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eSterile single-use vial\u003cbr\u003e\u003cbr\u003e\n\u003ch4 dir=\"ltr\" class=\"mt-2 -mb-1 text-base font-bold\"\u003eResearch Overview\u003c\/h4\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003eTirzepatide is a synthetic peptide investigated in scientific literature for its dual-incretin mechanism, engaging both GIP and GLP-1 receptor pathways. Research interest centers on its influence on glucose homeostasis, insulin secretion pathways, and energy metabolism in laboratory models. As a novel dual-agonist molecule, it continues to be a subject of ongoing academic and pharmaceutical research into incretin-based signaling.\u003cbr\u003e\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal\" dir=\"ltr\"\u003e\u003cstrong\u003eDon't forget your bacteriostatic water!\u003c\/strong\u003e\u003cbr\u003eThis product is supplied as a lyophilized (freeze-dried) powder and requires bacteriostatic water for reconstitution before research use. \u003ca class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/health-tech.co.za\/products\/bac-water-10ml\"\u003eShop our 10mL BAC Water →\u003c\/a\u003e\u003c\/p\u003e\n\u003cbr\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Health-Tech","offers":[{"title":"Default Title","offer_id":48858285211873,"sku":null,"price":1650.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/e38b2df2-2210-453f-bcd0-cf10816b2eff.png?v=1785926681"},{"product_id":"keifei-mounjafei-tirzepatide-pre-filled-disposeable-pen-10mg-ml","title":"Keifei Mounjafei® Tirzepatide 10mg\/ml Pre-filled Pen","description":"\u003ch1 class=\"PDq2pG_selectionAnchorContainer\"\u003eKeifei Mounjafei® Tirzepatide 10mg\/ml Pre-filled Pen\u003c\/h1\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eThe\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eKeifei Mounjafei® Tirzepatide 10mg\/ml Pre-filled Pen\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis a precision-manufactured research formulation containing tirzepatide, a dual\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eGLP-1 (Glucagon-Like Peptide-1)\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eand\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eGIP (Glucose-Dependent Insulinotropic Polypeptide)\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ereceptor agonist that has become a major focus within metabolic and obesity-related scientific research.\u003c\/p\u003e\n\u003cp\u003eIts convenient pre-filled pen design offers consistent preparation while supporting laboratory investigations into:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMetabolic regulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnergy balance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite signalling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGlucose homeostasis\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBody composition\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInsulin sensitivity\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eWeight management mechanisms\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKeifei's professional formulation is produced using high manufacturing standards, making it suitable for qualified laboratory and scientific research applications.\u003c\/p\u003e","brand":"Health-Tech","offers":[{"title":"Default Title","offer_id":48862077780193,"sku":null,"price":2100.0,"currency_code":"ZAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/5e47a075-7588-4ab0-b159-a20edc5c7796.png?v=1786007909"},{"product_id":"dex-pharma-mot-c-pro-40mg-3ml","title":"Dex Pharma Mot-C Pro 40mg\/3ml","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eProduct Description\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eDex Pharma MOTS-C Pro 40mg\/3ml Pen\u003c\/strong\u003e is a precision-formulated research peptide presented in a convenient pre-filled pen format,designed for laboratory and scientific investigation into mitochondrial function,cellular metabolism,and metabolic health.\u003c\/p\u003e\n\u003cp\u003eMOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a naturally occurring mitochondrial-derived peptide (MDP) that has become an important area of research due to its potential role in regulating energy metabolism,glucose homeostasis,insulin sensitivity,and exercise physiology.\u003c\/p\u003e\n\u003cp\u003eThe Dex Pharma pre-filled pen offers researchers a consistent and convenient presentation,eliminating the need for manual peptide reconstitution while providing accurate dispensing for controlled research protocols.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor Research Use Only. Not intended for human consumption or therapeutic use.\u003c\/strong\u003e\u003c\/p\u003e","brand":"Health-Tech","offers":[{"title":"Default Title","offer_id":48862330749153,"sku":null,"price":1700.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/ccadeea1-d539-45ed-873d-83be4692ccb5.png?v=1786011971"},{"product_id":"r3t-trutide-64mg-multi-dose-injection-pen","title":"Body Pharma R3t@trutide 64mg Multi-Dose Injection Pen","description":"\u003cp\u003e\u003cstrong\u003eRetatrutide 64mg Research Pen\u003c\/strong\u003e\u003cspan\u003e is a peptide research product featuring \u003c\/span\u003e\u003cstrong\u003eretatrutide (LY3437943)\u003c\/strong\u003e\u003cspan\u003e, an investigational triple receptor agonist that activates the \u003c\/span\u003e\u003cstrong\u003eGIP, GLP-1, and glucagon receptors\u003c\/strong\u003e\u003cspan\u003e. Retatrutide is currently being evaluated in clinical research programs investigating metabolic health, obesity, type 2 diabetes, and related cardiometabolic conditions. \u003cbr\u003e\u003cbr\u003e\u003c\/span\u003e\u003cspan\u003eThis \u003c\/span\u003e\u003cstrong\u003e64mg pre-filled research pen\u003c\/strong\u003e\u003cspan\u003e is designed for laboratory and research-focused applications, providing a convenient pen-format presentation for researchers working with retatrutide. The compound remains \u003c\/span\u003e\u003cstrong\u003einvestigational and is not currently FDA-approved for public use\u003c\/strong\u003e\u003cspan\u003e. \u003c\/span\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e","brand":"Body Pharma","offers":[{"title":"Default Title","offer_id":48951291216097,"sku":null,"price":4480.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/fe36db60-9b4c-4848-971b-7859d606c303.png?v=1785413795"},{"product_id":"keifei-r3t-trutifei-32-5mg-pen","title":"Keifei R3t@trutifei 32.5mg\/pen","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eR3t@trutifei 32.5mg\/Pen\u003c\/strong\u003e is a pre-filled research peptide pen developed for laboratory and preclinical investigation into metabolic regulation. As a triple receptor agonist, R3t@trutide has become a major focus of scientific research because of its ability to activate multiple hormonal pathways involved in energy balance, glucose regulation, and body weight.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThe convenient pre-filled pen format offers researchers a ready-to-use presentation,making it suitable for controlled laboratory protocols where precision and consistency are important.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e32.5mg R3t@trutifei per pre-filled pen\u003c\/strong\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/li\u003e\n\u003cli\u003eTriple-agonist peptide for metabolic research\u003c\/li\u003e\n\u003cli\u003ePrecision pre-filled pen presentation\u003c\/li\u003e\n\u003cli\u003eDesigned for laboratory and research applications\u003c\/li\u003e\n\u003cli\u003eIndividually packaged for quality assurance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eResearch Overview\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eR3t@trutide is an investigational peptide that acts on three metabolic receptors:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eGLP-1 (Glucagon-Like Peptide-1) Receptor\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGlucagon Receptor\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBy targeting all three pathways simultaneously,researchers are investigating its potential effects on:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMetabolic regulation\u003c\/li\u003e\n\u003cli\u003eEnergy expenditure\u003c\/li\u003e\n\u003cli\u003eAppetite signalling\u003c\/li\u003e\n\u003cli\u003eBody weight research\u003c\/li\u003e\n\u003cli\u003eGlucose homeostasis\u003c\/li\u003e\n\u003cli\u003eFat metabolism\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIts triple-agonist mechanism has made it one of the most actively studied compounds in modern metabolic research.\u003c\/p\u003e","brand":"Health Tech","offers":[{"title":"Default Title","offer_id":48951291281633,"sku":null,"price":2200.0,"currency_code":"ZAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/80ffe2fd-7bf0-4e1c-beb2-decd08d9b3d6.png?v=1785320933"},{"product_id":"upa-tidlira-30-tirzepetide-prefilled-pen","title":"UPA Tidlra 30mg Pre-Filled Pen | Research Peptide","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eUPA Tidlira 30 — Tirzepatide 30 mg Pre-Filled Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Health | Appetite Regulation | Weight-Management Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eUPA Tidlira 30 is a pre-filled pen labelled as containing 30 mg of tirzepatide, a dual GIP and GLP-1 receptor agonist studied extensively for its effects on metabolic health, appetite regulation and body-weight management.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts on two hormone receptor pathways involved in glucose regulation and energy balance. This dual mechanism has made it an important focus of clinical research into type 2 diabetes, obesity and associated metabolic complications.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Clinical Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003e1. Significant Body-Weight Reduction\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThe Phase 3 SURMOUNT-1 clinical trial, published in \u003c\/span\u003e\u003cem\u003e\u003cspan\u003eThe New England Journal of Medicine\u003c\/span\u003e\u003c\/em\u003e\u003cspan\u003e, evaluated tirzepatide in adults with obesity or overweight and at least one weight-related complication, excluding diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eAfter 72 weeks, average body-weight reductions were:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e5 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 15.0%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e10 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 19.5%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e15 mg trial group:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 20.9%\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese results demonstrated substantial average weight reduction under the specific conditions of the clinical trial. Individual outcomes varied, and these figures should not be interpreted as predicted results for this particular pen.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e2. Appetite and Energy-Balance Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts on GIP and GLP-1 receptors involved in appetite signalling and energy regulation. Clinical research has demonstrated meaningful effects on body weight, making these pathways an important area of investigation in obesity and metabolic health.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e3. Improved Blood-Glucose Regulation\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eIn the Phase 3 SURPASS-1 trial involving adults with type 2 diabetes, tirzepatide produced significant improvements in HbA1c, a measure of average blood-glucose levels, compared with placebo over 40 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe study also reported reductions in fasting blood glucose and body weight across the studied treatment groups.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e4. Cardiometabolic Improvements\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSURMOUNT-1 reported improvements in several prespecified cardiometabolic measures alongside weight reduction. These findings support continued research into the relationship between tirzepatide, excess body weight and metabolic risk factors.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e5. Long-Term Weight and Diabetes-Prevention Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eA subsequent three-year analysis of SURMOUNT-1 involving participants with obesity and prediabetes found sustained weight reduction and a substantially lower rate of progression to type 2 diabetes in the tirzepatide groups compared with placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis is an important research finding, although the results apply to the studied population and treatment regimen rather than to every tirzepatide-labelled product.\u003c\/span\u003e\u003c\/p\u003e","brand":"UPA","offers":[{"title":"Default Title","offer_id":49054842061025,"sku":null,"price":1790.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/UPATidlira.png?v=1788862813"},{"product_id":"upa-magtidelira-33-maglutide-33mg-pre-filled-pen-research-peptide","title":"UPA MAGTIDELIRA 33 (Maglutide 33mg) Pre-Filled Pen | Research Peptide","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eUPA Magtidelira 33 mg — Pre-Filled Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research | GLP-1 \u0026amp; GIP Signalling | Appetite Regulation\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eUPA Magtidelira 33 mg is a pre-filled pen-format product marketed as a hybrid formulation containing tirzepatide and semaglutide, with a labelled total strength of 33 mg.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts on two metabolic hormone receptors, GIP and GLP-1, while semaglutide selectively activates the GLP-1 receptor. These pathways are involved in appetite signalling, blood-glucose regulation and energy balance.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBoth compounds have been extensively studied in clinical research, particularly in relation to type 2 diabetes and weight management. However, their combination in a single product is a separate formulation that requires its own evidence of safety, quality and efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Clinical Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003e1. Body-Weight Reduction\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eIn the 72-week SURMOUNT-1 trial, average body-weight reductions with tirzepatide were 15.0%, 19.5% and 20.9% across the three studied dose groups.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn the 68-week STEP 1 trial, semaglutide 2.4 mg produced an average body-weight reduction of approximately 14.9%, compared with 2.4% with placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese results demonstrate the potential of the individual medicines in their studied populations. They are not predictions of weight loss from Magtidelira.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e2. Appetite Regulation\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide and semaglutide influence incretin pathways involved in appetite and food intake. Clinical studies of their respective authorised formulations have demonstrated meaningful effects on body weight.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eHowever, there is insufficient clinical evidence to conclude that combining both compounds produces greater appetite control or superior weight-loss outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e3. Blood-Glucose Regulation\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eBoth medicines have demonstrated improvements in blood-glucose control in clinical trials involving people with type 2 diabetes. Tirzepatide's dual GIP\/GLP-1 receptor activity and semaglutide's GLP-1 receptor activity have been studied in their respective authorised formulations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThese findings cannot establish the efficacy or safety of an unverified combination product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e4. Metabolic Health Research\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials of tirzepatide and semaglutide have examined changes in body weight and several cardiometabolic markers. The findings have contributed to significant scientific interest in incretin-based treatments for metabolic health.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe extent to which these outcomes apply to Magtidelira is unknown without appropriate product-specific clinical evidence.\u003c\/span\u003e\u003c\/p\u003e","brand":"UPA","offers":[{"title":"Default Title","offer_id":49054988239073,"sku":null,"price":1990.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/UPAMagtidelira33.png?v=1788864967"},{"product_id":"hd-labs-r3t-trutide-32mg-research-peptide-vial","title":"HD Labs R3t@trutide 32mg Research Peptide Vial","description":"\u003ch3 class=\"PDq2pG_selectionAnchorContainer\"\u003eHD Labs R3t@trutide 32mg Research Peptide Vial\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHD Labs R3t@trutide 32mg\u003c\/strong\u003e is a research-focused peptide supplied in a \u003cstrong\u003e32mg vial\u003c\/strong\u003e format for laboratory and scientific research applications.\u003c\/p\u003e\n\u003cp\u003eR3t@trutide is an investigational peptide associated with research into activity involving the \u003cstrong\u003eGIP, GLP-1 and glucagon receptors\u003c\/strong\u003e. The compound is also referenced by the research code \u003cstrong\u003eLY3437943\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThis HD Labs \u003cstrong\u003e32mg R3t@trutide research peptide\u003c\/strong\u003e is supplied in vial format for research applications and scientific investigation.\u003c\/p\u003e\n\u003cp class=\"t4s-product__title\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eBacteriostatic Water 0,3ml Included.\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 class=\"PDq2pG_selectionAnchorContainer\"\u003eKey Product Details\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBrand:\u003c\/strong\u003e HD Labs\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e R3t@trutide 32mg\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAlternative Reference:\u003c\/strong\u003e LY3437943\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrength:\u003c\/strong\u003e 32mg per vial\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Research Peptide Vial\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResearch Classification:\u003c\/strong\u003e Investigational Peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReceptor Research:\u003c\/strong\u003e GIP \/ GLP-1 \/ Glucagon\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntended Application:\u003c\/strong\u003e Laboratory and Scientific Research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eResearch Information\u003c\/h3\u003e\n\u003cp\u003eR3t@trutide is an investigational peptide currently being studied for its activity across \u003cstrong\u003eGIP, GLP-1 and glucagon receptors\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThis product is supplied for \u003cstrong\u003eresearch purposes only\u003c\/strong\u003e and is not presented as an approved medicine, dietary supplement or treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor research purposes only. Not intended for human or veterinary use.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"t4s-product__title\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"HD Labs","offers":[{"title":"Default Title","offer_id":49078225699041,"sku":null,"price":1650.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/HDLabsR3t_32.png?v=1789038145"},{"product_id":"upa-upret-60-retatrutide-60mg-peptide-aesthetix","title":"UPA UPRET 60 Retatrutide 60mg | Peptide Aesthetix","description":"\u003cp dir=\"auto\" class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eUPA UPRET 60\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis a high-strength\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e60mg retatrutide\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eresearch peptide supplied in a multidose vial presentation. Retatrutide is an investigational triple-receptor agonist that has been studied for its activity at the\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eGLP-1, GIP and glucagon (GCG) receptors\u003c\/strong\u003e.\u003cspan\u003e \u003c\/span\u003e\u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003eThe supplied UPA presentation includes\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e1 × 60mg multidose vial\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eand\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e1 × 2mL bacteriostatic water ampoule\u003c\/strong\u003e, according to the manufacturer's current product information and the packaging shown.\u003cspan\u003e \u003c\/span\u003e\u003c\/p\u003e","brand":"UPA","offers":[{"title":"Default Title","offer_id":49136405741793,"sku":null,"price":2700.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/79bdf96c-25eb-49ae-b11e-d65490cd3fed.png?v=1789557009"},{"product_id":"pure-eloralintide-10mg-selective-amylin-research-peptide","title":"Pure Eloralintide 10mg | Selective Amylin Research Peptide","description":"\u003ch3 data-section-id=\"n3c97h\" dir=\"auto\" data-start=\"1305\" data-end=\"1331\" class=\"PDq2pG_selectionAnchorContainer\"\u003ePure Eloralintide 10mg\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp dir=\"auto\" data-start=\"1333\" data-end=\"1400\"\u003e\u003cstrong data-start=\"1333\" data-end=\"1400\"\u003eResearch Grade • 10mg Reference Strength • Third-Party Verified\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\" data-start=\"1402\" data-end=\"1615\"\u003ePure Eloralintide 10mg is a research-grade peptide containing \u003cstrong data-start=\"1464\" data-end=\"1492\"\u003eeloralintide (LY3841136)\u003c\/strong\u003e, an investigational long-acting selective amylin receptor agonist being studied in metabolic and obesity-related research.\u003c\/p\u003e\n\u003cp dir=\"auto\" data-start=\"1617\" data-end=\"1873\"\u003eEloralintide is designed to preferentially activate the \u003cstrong data-start=\"1673\" data-end=\"1702\"\u003eamylin 1 receptor (AMY1R)\u003c\/strong\u003e, providing researchers with a distinct pathway for investigating appetite, satiety, food-intake regulation and metabolic signalling. \u003cspan class=\"contents\" data-content-reference-start=\"1842\" data-content-reference-end=\"1874\"\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-section-id=\"15v820j\" dir=\"auto\" data-start=\"1875\" data-end=\"1893\"\u003eResearch Focus\u003c\/h3\u003e\n\u003cp dir=\"auto\" data-start=\"1895\" data-end=\"1986\"\u003eEloralintide is currently being investigated across clinical research programmes examining:\u003c\/p\u003e\n\u003cul data-start=\"1988\" data-end=\"2224\"\u003e\n\u003cli data-section-id=\"wrqebw\" data-start=\"1988\" data-end=\"2016\"\u003eAmylin receptor signalling\u003c\/li\u003e\n\u003cli data-section-id=\"9d455p\" data-start=\"2017\" data-end=\"2048\"\u003eAppetite and satiety pathways\u003c\/li\u003e\n\u003cli data-section-id=\"1oivqq7\" data-start=\"2049\" data-end=\"2073\"\u003eFood-intake regulation\u003c\/li\u003e\n\u003cli data-section-id=\"r5h5xo\" data-start=\"2074\" data-end=\"2096\"\u003eBody-weight research\u003c\/li\u003e\n\u003cli data-section-id=\"1qxzlwn\" data-start=\"2097\" data-end=\"2117\"\u003eMetabolic research\u003c\/li\u003e\n\u003cli data-section-id=\"tc4qzw\" data-start=\"2118\" data-end=\"2144\"\u003eObesity-related research\u003c\/li\u003e\n\u003cli data-section-id=\"1cbxksk\" data-start=\"2145\" data-end=\"2197\"\u003eCombination approaches involving incretin pathways\u003c\/li\u003e\n\u003cli data-section-id=\"14x05md\" data-start=\"2198\" data-end=\"2224\"\u003eCardiometabolic research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"auto\" data-start=\"2226\" data-end=\"2546\"\u003eCurrent clinical development includes Phase 3 studies evaluating eloralintide in different obesity and overweight research populations, including studies involving type 2 diabetes, obstructive sleep apnea, osteoarthritis and combination therapy with weekly incretin-based treatment.\u003c\/p\u003e","brand":"Pure Performance Labs","offers":[{"title":"Default Title","offer_id":50673265836257,"sku":null,"price":2399.0,"currency_code":"ZAR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/PureEloralintide_f3059c03-0586-4367-85b3-7dbe16ff08cc.png?v=1790929899"},{"product_id":"hd-labs-tirzepatide-60","title":"HD Labs Tirzepatide 60mg Vial","description":"\u003ch3\u003e\u003cspan\u003eHD Labs Tirzepatide 60mg\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eHD Labs Tirzepatide 60mg\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is a research-grade peptide reference material featuring \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003etirzepatide\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, a synthetic peptide studied for its activity at both the \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eglucose-dependent insulinotropic polypeptide (GIP) receptor\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e and \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eglucagon-like peptide-1 (GLP-1) receptor\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe product shown is labelled as \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e60mg per vial\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e and is presented by HD Labs as a peptide research product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eResearch Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide is notable within peptide research because it interacts with two incretin-related receptor pathways rather than targeting GLP-1 alone. FDA clinical pharmacology information describes tirzepatide as a \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eGIP and GLP-1 receptor agonist\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e and reports effects involving appetite regulation, insulin secretion, glucagon secretion and gastric emptying. \u003c\/span\u003e\u003cspan\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217806s013lbl.pdf?utm_source=chatgpt.com\"\u003eAccess Data\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis dual-receptor activity has made tirzepatide an important subject of ongoing research involving:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan\u003eGIP receptor signalling\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eGLP-1 receptor signalling\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eMetabolic regulation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eGlucose-dependent insulin secretion\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eGlucagon regulation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAppetite and energy-intake pathways\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eGastric-emptying research\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eBody-composition and metabolic research\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"HD Labs","offers":[{"title":"Default Title","offer_id":50762816684257,"sku":null,"price":2600.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/TirzepatideLabsBoxinCosmicBlue.png?v=1791291176"},{"product_id":"r3tatrutide-32-mg","title":"Noventra Labs R3t@trutide 32 mg","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eNoventra Pharma R3t@trutide 32 mg — Multidose Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTriple-Receptor Research | Metabolic Health | Weight-Management Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eNoventra Pharma R3t@trutide 32 mg Multidose Pen is a pre-filled pen-format product labelled with a total strength of 32 mg and a 200-click mechanism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eR3t@trutide is an investigational compound attracting considerable scientific interest for its unique activity across three metabolic hormone receptors: GLP-1, GIP and glucagon. These pathways are being studied for their roles in appetite signalling, energy balance, glucose regulation and body-weight changes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe multidose pen format offers a compact, integrated presentation, with the product packaging specifying a multi-dose pen design and single-patient use.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eClinical studies have reported promising results for retatrutide in adults living with obesity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSignificant body-weight reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e In a Phase 2 clinical trial, the group receiving the highest studied dose experienced an average body-weight reduction of 24.2% after 48 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eReduced waist circumference:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Participants experienced reductions in waist circumference across the studied treatment groups.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic markers:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Researchers observed improvements in several cardiometabolic measures, including blood glucose, HbA1c, blood pressure and certain lipid measurements.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTriple-receptor mechanism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Retatrutide activates GLP-1, GIP and glucagon receptors, making it a distinctive subject of ongoing metabolic research.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Noventra","offers":[{"title":"Default Title","offer_id":51026672648417,"sku":null,"price":2080.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/ef9cf187-693a-4214-89ae-a68b27de5a83.png?v=1792585614"},{"product_id":"retatrutide-32-mg-self-mix","title":"Noventra R3t@trutide 32 mg Self-Mix","description":"\u003ch1 data-pm-slice=\"1 3 []\"\u003e\u003cspan\u003eNoventra Pharma Retatrutide 32 mg — Multi-Dose Ampule\u003c\/span\u003e\u003c\/h1\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Description\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eExplore the science behind next-generation metabolic research with \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eNoventra Pharma Retatrutide 32 mg\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, a multi-dose ampule presented in a pharmaceutical-style research format.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eRetatrutide is an investigational triple-hormone receptor agonist designed to activate three pathways involved in metabolic regulation: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis triple-receptor activity has made retatrutide a significant subject of clinical research into body-weight regulation, glucose metabolism, and cardiometabolic health.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003eProduct Specifications\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBrand:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Noventra Pharma\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCompound:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Retatrutide\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eLabelled strength:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 32 mg\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eFormat:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Multi-dose ampule\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003ePresentation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 1 × 32 mg ampule\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAdditional item shown on packaging:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e 1 × 2 ml bacteriostatic water ampule\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eResearch category:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Metabolic and incretin-pathway research\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e\u003cspan\u003eKey Research Areas\u003c\/span\u003e\u003c\/h3\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBody-weight regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigated for its potential effects on body weight and energy balance.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAppetite-related pathways:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Studied through GLP-1 and GIP receptor signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eGlucose metabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Investigated for effects on glycaemic markers and insulin-related measures.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiometabolic markers:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical research has examined changes in waist circumference, blood pressure, and blood lipid measurements.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTriple-receptor activity:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Combines GIP, GLP-1, and glucagon receptor agonism in a single investigational molecule.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Noventra","offers":[{"title":"Default Title","offer_id":51026675073249,"sku":null,"price":1540.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra-Pharma-Retatrutide-32mg-Multi-Dose-Ampule-Self-Mix-card-768x538.png?v=1792585096"},{"product_id":"tirzepatide-30-mg","title":"Noventra Tirzepatide 30 mg Research Pen","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eNoventra Pharma Tirzepatide 30 mg — Multidose Pen\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eDual-Receptor Research | Metabolic Health | Weight-Management Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eNoventra Pharma Tirzepatide 30 mg Multidose Pen is a pen-format product labelled with a total strength of 30 mg and a 200-click mechanism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide is a dual GIP and GLP-1 receptor agonist studied for its effects on blood-glucose regulation, appetite signalling and body-weight management. By acting on two metabolic hormone pathways, tirzepatide has become an important subject of clinical research into obesity and type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe pen format provides an integrated, compact presentation, with the packaging specifying a multidose design and single-patient use.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Clinical Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003ePublished clinical trials have demonstrated meaningful effects from tirzepatide in studied patient populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eSignificant body-weight reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e In the 72-week SURMOUNT-1 clinical trial, average body-weight reductions ranged from 16.0% to 22.5% across the three studied tirzepatide dose groups.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAppetite and energy intake:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Research into tirzepatide's mechanism has shown effects on appetite regulation and food intake, contributing to its investigation as a weight-management treatment.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBlood-glucose regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Tirzepatide has demonstrated improvements in glycaemic control in clinical studies involving people with type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic health:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical research has also reported improvements in several weight-related cardiometabolic measures, although outcomes vary between individuals and study populations.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThe SURMOUNT-1 results were obtained in adults with obesity or overweight and at least one weight-related complication, excluding diabetes. These results relate to the studied medicinal formulations and treatment protocols; they do not establish the performance of this specific retail product.\u003c\/span\u003e\u003c\/p\u003e","brand":"Noventra","offers":[{"title":"Default Title","offer_id":51026677760225,"sku":null,"price":1930.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra-Pharma-Tirzepatide-30mg-2ml-Multi-Dose-Pen-200-Clicks-card-768x329.png?v=1793174565"},{"product_id":"tirzepatide-30-mg-self-mix","title":"Noventra Pharma Tirzepatide 30 mg Self-Mix","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eNoventra Pharma Tirzepatide 30 mg — Multidose Vial Kit\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eDual-Receptor Research | Metabolic Health | Weight-Management Research\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eNoventra Pharma Tirzepatide 30 mg is a vial-format product labelled as containing a 30 mg multidose ampule, accompanied by a 2 ml ampule of bacteriostatic water.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide is a dual GIP and GLP-1 receptor agonist studied for its role in appetite regulation, blood-glucose control and body-weight management. Its activity across these two metabolic hormone pathways has made it an important focus of clinical research into obesity and type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eKey Research Findings\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials have demonstrated several important effects of tirzepatide in studied patient populations:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBody-weight reduction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e In the 72-week SURMOUNT-1 trial, average body-weight reductions ranged from 15.0% to 20.9% across the three tirzepatide groups in the primary analysis.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eAppetite regulation:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Tirzepatide influences metabolic signalling pathways involved in appetite and energy intake.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBlood-glucose control:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Clinical research has demonstrated improvements in glycaemic control among people with type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eCardiometabolic markers:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Trials reported improvements in waist circumference, blood pressure and several blood lipid measurements.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThese findings reflect outcomes from controlled clinical trials using specified tirzepatide formulations and treatment protocols. They do not establish equivalent results for this particular product.\u003c\/span\u003e\u003c\/p\u003e","brand":"Noventra","offers":[{"title":"Default Title","offer_id":51026680873185,"sku":null,"price":1440.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra-Pharma-Tirzepatide-30mg-Multi-Dose-Ampule-Self-Mix-card-768x538.png?v=1793173278"},{"product_id":"tirreta-60-mg-self-mix","title":"Noventra Pharma TirReta 60 mg Self-Mix","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003e\u003cspan\u003eNoventra Pharma TirReta 60 mg — Self-Mix Vial Kit\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eMetabolic Research | Dual-Compound Formulation | GLP-1, GIP \u0026amp; Glucagon Pathways\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eProduct Overview\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eNoventra Pharma TirReta 60 mg is a self-mix vial-format product labelled as containing a 60 mg multidose ampule, supplied with a separate 2 ml ampule of bacteriostatic water.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThe manufacturer's online listing identifies TirReta as a combination of \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003e30 mg tirzepatide and 30 mg retatrutide\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e. Confirm this composition against the current product label and batch documentation before relying on it.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eTirzepatide acts on GIP and GLP-1 receptors, while retatrutide is an investigational compound that activates GIP, GLP-1 and glucagon receptors. These pathways are being studied for their roles in appetite signalling, glucose regulation, energy balance and body-weight management.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eResearch Background\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTirzepatide\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eClinical trials have demonstrated improvements in blood-glucose control in people with type 2 diabetes and significant average body-weight reductions in adults with obesity or overweight in dedicated weight-management studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eRetatrutide\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIn a Phase 2 obesity trial, retatrutide produced substantial average body-weight reductions over 48 weeks. Its triple-receptor mechanism remains under investigation, and additional research is needed to establish its safety and efficacy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant distinction:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e These findings relate to the individual compounds studied in controlled clinical trials. They do not demonstrate that combining the two compounds produces greater benefits, or establish the safety, effectiveness or stability of this particular formulation.\u003c\/span\u003e\u003c\/p\u003e","brand":"Noventra","offers":[{"title":"Default Title","offer_id":51026689491169,"sku":null,"price":1640.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/files\/Noventra-Pharma-TirReta-60mg-Multi-Dose-Ampule-Self-Mix-card-768x538.png?v=1793173449"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0825\/1935\/9713\/collections\/weight.jpg?v=1778034741","url":"https:\/\/health-tech.co.za\/collections\/weight.oembed?page=3","provider":"Health Tech","version":"1.0","type":"link"}